Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether adding low-dose intra-arterial alteplase immediately after successful endovascular thrombectomy improves recovery in adults who have suffered an acute ischemic stroke caused by blockage in the large arteries of the brains anterior circulation. This phase 3, multicenter, randomized study compares functional outcomes between patients receiving adjunctive alteplase plus standard care and those receiving standard care alone after thrombectomy. The goal is to determine if this combined treatment enhances neurological recovery without increasing major bleeding or death risks. Participants who have a confirmed large vessel occlusion stroke and achieve successful reperfusion eTICI 2b-3 within 24 hours of symptom onset will be randomly assigned to either receive intra-arterial alteplase plus best medical management or best medical management alone. The alteplase dose is 0.225 mgkg up to a maximum of 22.5 mg, given immediately after thrombectomy. Endovascular thrombectomy is performed using approved techniques and devices according to guidelines. The study follows a parallel design with two treatment groups. During the trial, participants will be assessed for neurological function and safety outcomes including symptomatic intracranial hemorrhage and mortality. The main measure is excellent functional outcome at 90 days, defined by a modified Rankin Scale score of 0-1. Secondary assessments include quality of life, stroke severity scores, reperfusion grade, and cost-effectiveness up to 12 months. Follow-up visits and evaluations will track recovery and safety over this period.